Ignite Creation Date:
2024-05-05 @ 11:30 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00067951
Status:
COMPLETED
Last Update Posted:
2018-03-21
First Post:
2003-09-03
Brief Title:
A Study To Evaluate The Safety And Efficacy Of An Investigational Diabetes Drug In Poorly Controlled Type II Diabetics
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
An Open-label Trial to Evaluate the Safety and Efficacy of Fixed Dose RosiglitazoneMetformin Combination Therapy in Poorly-controlled Subjects With Type 2 Diabetes Mellitus
Status:
COMPLETED
Status Verified Date:
2018-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this research study is to determine if a new investigational diabetes drug is safe and effective in treating people who have Type II diabetes mellitus with very high HbA1c or FPG fasting plasma glucose levels The HbA1c test also called the hemoglobin A1c test or glycated hemoglobin test is a measurement of the average amount of sugar in the blood over the last 2 to 3 months FPG is a test that measures the amount of sugar in the blood after an 8 hour fast
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None